These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4428503)

  • 21. A biomedical computer programme system for controlled trials.
    Juhl E; Winkel P; Frank H; Tygstrup N
    Scand J Gastroenterol Suppl; 1970; 7():195-201. PubMed ID: 4917039
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunosuppressive therapy of chronic aggressive hepatitis and primary biliary cirrhosis].
    Lampe K; Hüdepohl M; Schopen RD
    Med Klin; 1972 Apr; 67(15):527-34. PubMed ID: 5053009
    [No Abstract]   [Full Text] [Related]  

  • 23. [Experience with the therapy of ascitic cirrhoses].
    Findo B; Dornetzhuber V
    Bratisl Lek Listy; 1970 Apr; 53(4):468-79. PubMed ID: 5447160
    [No Abstract]   [Full Text] [Related]  

  • 24. [Long-term therapy of chronic hepatitis].
    De Groote J; Maes H; Vandenbroucke J
    Dtsch Z Verdau Stoffwechselkr; 1970; 30(1):15-7. PubMed ID: 5501420
    [No Abstract]   [Full Text] [Related]  

  • 25. A therapeutic index that predicts the individual effects of prednisone in patients with cirrhosis.
    Christensen E; Schlichting P; Andersen PK; Fauerholdt L; Juhl E; Poulsen H; Tygstrup N
    Gastroenterology; 1985 Jan; 88(1 Pt 1):156-65. PubMed ID: 3880556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Survival of ascitic alcoholic cirrhosis patients. Comparison of results from 3 surveys during a 20-year period].
    Justin-Besançon L; Durand H; Dorfmann H; Gueroult N; Voisin PM; Roge J; Etienne JP
    Ann Med Interne (Paris); 1971 Jan; 122(1):49-54. PubMed ID: 5548149
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hepatic cirrhosis in Warsaw with special reference to the causative factor of viral hepatitis].
    Magdzik W; Gonera E
    Przegl Epidemiol; 1970; 24(3):357-68. PubMed ID: 5482216
    [No Abstract]   [Full Text] [Related]  

  • 28. Posthepatitic portal fibrosis: resolution associated with corticosteroid therapy.
    Golden D
    Am J Gastroenterol; 1968 May; 49(5):430-5. PubMed ID: 5659757
    [No Abstract]   [Full Text] [Related]  

  • 29. [Alcoholic cirrhosis and Launois-Bensaude disease. Historical, clinical and pathogenic study of diffuse symmetrical lipomatosis of cervical predominance].
    Deparis M; Sarrazin A; Auzépy P; Robineau M; Forti MF
    Rev Int Hepatol; 1968; 18(6):799-821. PubMed ID: 5702103
    [No Abstract]   [Full Text] [Related]  

  • 30. Mortality from cirrhosis of the liver--United States, Canada, and Western Europe.
    Stat Bull Metropol Life Insur Co; 1973 Oct; 54():5-8. PubMed ID: 4764621
    [No Abstract]   [Full Text] [Related]  

  • 31. A controlled study of the therapeutic portacaval shunt.
    Resnick RH; Iber FL; Ishihara AM; Chalmers TC; Zimmerman H
    Gastroenterology; 1974 Nov; 67(5):843-57. PubMed ID: 4547724
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative studies with short-term prednisone treatment of diabetics and non-diabetics with chronic hepatitis and liver cirrhosis with special consideration of carbohydrate metabolism].
    Takác A; Bruns W; Langsch HG; Vetter K; Kublun G
    Dtsch Z Verdau Stoffwechselkr; 1965 Nov; 25(5):312-7. PubMed ID: 5888992
    [No Abstract]   [Full Text] [Related]  

  • 33. [Use of diuretics from the functional viewpoint. 7. Treatment of edema. (2). Treatment of edema and ascites caused by heart failure or liver cirrhosis].
    Furukawa T
    Saishin Igaku; 1965 Jul; 20(7):1743-58. PubMed ID: 5884753
    [No Abstract]   [Full Text] [Related]  

  • 34. [Survival in alcoholic cirrhosis after decompensation].
    Prost G; Dechavanne ; Martin C; Evreux M; Tolot F
    Nouv Presse Med; 1972 Dec; 1(45):3031-3. PubMed ID: 4539729
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of ascitic cirrhosis with delta-cortisone and delta-hydrocortisone].
    CATTAN R; VESIN P
    Therapie; 1957; 12(4):601-12. PubMed ID: 13467836
    [No Abstract]   [Full Text] [Related]  

  • 36. [Correction by L-dopa of neurologic manifestations of a chronic portocaval encephalopathy].
    Girard PF; Trillet M; Kopp N
    Rev Neurol (Paris); 1972 Nov; 127(5):560-3. PubMed ID: 4668744
    [No Abstract]   [Full Text] [Related]  

  • 37. High doses of spironolactone in the treatment of liver cirrhosis with ascites.
    Papadoyanakis N; Darsinos J; Alexandrou K; Karli J
    Br J Clin Pract; 1972 Jan; 26(1):27-32. PubMed ID: 5025912
    [No Abstract]   [Full Text] [Related]  

  • 38. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables.
    Christensen E; Schlichting P; Andersen PK; Fauerholdt L; Schou G; Pedersen BV; Juhl E; Poulsen H; Tygstrup N
    Scand J Gastroenterol; 1986 Mar; 21(2):163-74. PubMed ID: 3520795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Saluretics in liver diseases].
    Dorner M; Frey G
    Munch Med Wochenschr; 1966 Dec; 108(51):2583-4. PubMed ID: 6013308
    [No Abstract]   [Full Text] [Related]  

  • 40. [Lipodystrophy of the liver and steroid treatment of chronic liver diseases].
    Nicolaescu T; Bordeianu A; Bittman E; Dragulescu N
    Rev Int Hepatol; 1967; 17(4):367-76. PubMed ID: 6048616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.